Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Faron announces its unaudited interim results for the six months ended 30 June 2019.
OncoCyte, a global oncology diagnostics company, recently announced that it will acquire Razor Genomics, which has developed a novel molecular diagnostic test for early-stage non-small cell lung cancer.
Using a combination of machine learning and parallel chemistry to change the way we think about treating disease
The dermatological drug maker will use Chapter 11 protection to restructure the company, including a possible sale of assets, and will delay development of its Phase III-ready psoriasis treatment.
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens.
CMR Surgical Limited announces that it has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
Race Oncology Limited is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.
Khanu Management GmbH, a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG, based in Dortmund, Germany.
New facilities expand services offering to Irish and International customers
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.